The OptiLink HF study is designed to randomize 1000 patients to investigate whether OptiVol fluid status monitoring reduces all-cause death and cardiovascular hospitalizations by 30%.
RCT (n=1,000)
Does OptiVol fluid status monitoring with wireless CareAlert notification reduce all-cause death and cardiovascular hospitalizations in patients with chronic heart failure and an ICD/CRT-D?
The OptiLink HF study is designed to evaluate whether wireless fluid status monitoring reduces mortality and cardiovascular hospitalizations in heart failure patients with ICD/CRT-D devices.
AIMS: The Optimization of Heart Failure Management using OptiVol Fluid Status Monitoring and CareLink (OptiLink HF) study is designed to investigate whether OptiVol fluid status monitoring with an automatically generated wireless CareAlert notification via the CareLink Network can reduce all-cause death and cardiovascular hospitalizations in an HF population, compared with standard clinical assessment. Methods Patients with newly implanted or replacement cardioverter-defibrillator devices with or without cardiac resynchronization therapy, who have chronic HF in New York Heart Association class II or III and a left ventricular ejection fraction ≤35% will be eligible to participate. Following device implantation, patients are randomized to either OptiVol fluid status monitoring through CareAlert notification or regular care (OptiLink 'on' vs. 'off'). The primary endpoint is a composite of all-cause death or cardiovascular hospitalization. It is estimated that 1000 patients will be required to demonstrate superiority of the intervention group to reduce the primary outcome by 30% with 80% power. CONCLUSION: The OptiLink HF study is designed to investigate whether early detection of congestion reduces mortality and cardiovascular hospitalization in patients with chronic HF. The study is expected to close recruitment in September 2012 and to report first results in May 2014.
Brachmann et al. (Tue,) conducted a rct in Chronic heart failure (n=1,000). OptiVol fluid status monitoring with CareAlert notification vs. Regular care (standard clinical assessment) was evaluated on Composite of all-cause death or cardiovascular hospitalization. The OptiLink HF study is designed to randomize 1000 patients to investigate whether OptiVol fluid status monitoring reduces all-cause death and cardiovascular hospitalizations by 30%.